RBM3 and ovarian carcinoma: Compared to previous studies that have reported the prognostic relevance of RBM3 in ovarian cancer, our study adds value by utilizing one of the largest TMA-based cohorts to date, applying a statistically validated cutoff scoring system, and focusing on a reproducible nuclear scoring method.